EU Clinical Trial 2018-004792-13

A randomized, double-blind, placebo controlled, parallel group, multicentric, phase IIa clinical trial to evaluate the safety, tolerability and therapeutic efficacy of daily oral treatment with NFX88 on neuropathic pain in patients with spinal cord injury.  May 23, 2019

Main objective of the trial: The primary objective is to assess the safety and tolerability of NFX88 in spinal cord injury patients with neuropathic pain over ninety-day treatment period. El objetivo principal del ensayo será evaluar la seguridad y la tolerabilidad de NFX88 en pacientes con lesión de médula espinal y dolor neuropático durante noventa días.



JSON preview

Similar records


Source:  EMA Last updated:  May 30, 2019

From, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.